Betaxolol eye drops 0.5% 5 ml N1 fl-drops
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Betaxolol
Composition
Eye drops in the form of a clear, colorless or slightly yellowish liquid. 1 ml of betaxolol (in the form of hydrochloride) 5 mg Excipients: sodium chloride 8 mg, disodium edetate dihydrate 0.1 mg, benzethonium chloride 0.1 mg, hydrochloric acid 1 M or sodium hydroxide 1 M to pH 6.0-7.8, purified water to 1 ml.
Pharmacological effect
Cardioselective beta1-blocker without internal sympathomimetic activity. It has a weak membrane stabilizing activity. It has a hypotensive effect associated with a decrease in the minute volume of the heart and a decrease in sympathetic stimulation of peripheral vessels. When used in therapeutic doses, it does not have a cardiodepressive effect, does not affect glucose metabolism, does not reduce the bronchodilatory effect of beta-adrenomimetics, does not cause a delay of sodium ions in the body. Acts for a long time. When applied topically in the form of eye drops lowers increased intraocular pressure. Resorptive effect is expressed slightly.
Indications
For systemic use: as a monotherapy and as part of a combination therapy, arterial hypertension, prevention of strokes of exertional angina. For local use in ophthalmology: chronic open-angle glaucoma, increased intraocular pressure, the state after laser trabeculoplasty.
Use during pregnancy and lactation
It should be used with caution in bronchial asthma and COPD moderate flow (start treatment with small doses and preferably under the control of indicators of respiratory function, due to beta1-selectivity of Betaxolol in the event of an asthma attack against the background of its reception, it is possible to stop the beta-adrenomimetic attack). in chronic heart failure in the stage of compensation (treatment with betaxolol is possible only under strict medical supervision. treatment should be started with very small doses with a gradual increase). with AV block I degree (requires careful observation, including ECG control). with obliterating diseases of the peripheral arteries, Raynaud's syndrome (except for the severe form) (possible increase in peripheral circulatory disorders). with Prinzmetal angina(perhaps an increase in angina attacks. Selective beta-1 blocker is possible only with simultaneous use of vasodilators). with treated pheochromocytoma (requires careful monitoring of blood pressure indicators). in elderly patients (treatment should be started with small doses and under careful medical supervision). in case of renal insufficiency (if QC is more than 20 ml / min, careful observation of the patient during the first few days of treatment. If QC is less than 20 ml / min and / or hemodialysis, correction of the dosage regimen is required). in case of liver failure (more careful clinical observation is required at the beginning of treatment). in patients with diabetes mellitus (regular monitoring of glucose concentration in the blood, including active self-control by the patient, is necessary at the beginning of treatment. decrease in the severity of precursors of hypoglycemia, such as tachycardia, palpitations and increased sweating). with psoriasis (beta-blockers can worsen the course of psoriasis). during desensitization therapy. The abolition of betaxolol should be carried out gradually, especially in patients with coronary artery disease, angina. Betaxolol does not affect the size of the pupil, therefore, in case of angle-closure glaucoma, the drug should be used only in combination with myotics. When transferring the patient to betaxolol after treatment with several antiglaucoma drugs, the latter are gradually canceled, at least 1 week per drug. With the simultaneous use of betaxolol in the form of eye drops and beta-blockers inside, it is possible to develop additive effects from both intraocular pressure and manifestations of the systemic action of beta-blockers. Before performing a planned operation, beta-blockers, incl. betaxolol should be undone. With topical application of Betaxolol, contact lenses should not be worn. It is not recommended to use Betaxolol in children. Influence on the ability to drive motor vehicles and control mechanisms With caution used in patients whose activities require increased attention and quick psychomotor reactions.
Side effects
Since the cardiovascular system: at the beginning of treatment - AV-blockade, sinus bradycardia, arterial hypotension, heart failure, Raynaud's syndrome. On the part of the digestive system: rarely - abdominal pain, nausea, vomiting.From the side of the central nervous system and peripheral nervous system: at the beginning of treatment - asthenia, paresthesias of the extremities, sleep disorders, depression, drowsiness, dizziness. On the part of the respiratory system: rarely - bronchospasm. Allergic reactions: rarely - psoriasis-like skin manifestations. Local reactions: when applied in the form of eye drops immediately after instillation, short-term discomfort in the eyes is possible, sometimes tearing. rarely, a decrease in corneal sensitivity, erythema, pruritus, spotty staining of the cornea, keratitis, anisocoria, photophobia.
special instructions
Since the cardiovascular system: at the beginning of treatment - AV-blockade, sinus bradycardia, arterial hypotension, heart failure, Raynaud's syndrome. On the part of the digestive system: rarely - abdominal pain, nausea, vomiting. From the side of the central nervous system and peripheral nervous system: at the beginning of treatment - asthenia, paresthesias of the extremities, sleep disorders, depression, drowsiness, dizziness. On the part of the respiratory system: rarely - bronchospasm. Allergic reactions: rarely - psoriasis-like skin manifestations. Local reactions: when applied in the form of eye drops immediately after instillation, short-term discomfort in the eyes is possible, sometimes tearing. rarely, a decrease in corneal sensitivity, erythema, pruritus, spotty staining of the cornea, keratitis, anisocoria, photophobia.